• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    2/1/24 4:31:08 PM ET
    $ADAG
    $ALZN
    $BRTX
    $CDXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email

    Gainers

    • MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 9.3% to $0.15 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million.
    • PaxMedica (NASDAQ:PXMD) shares rose 8.58% to $0.54. The company's market cap stands at $2.4 million.
    • Oragenics (AMEX:OGEN) shares moved upwards by 6.98% to $2.45. The market value of their outstanding shares is at $7.5 million.
    • Lineage Cell Therapeutics (AMEX:LCTX) shares moved upwards by 6.62% to $0.92. The market value of their outstanding shares is at $160.9 million.
    • BioRestorative Therapies (NASDAQ:BRTX) shares rose 6.01% to $2.29. The market value of their outstanding shares is at $10.7 million.
    • Codexis (NASDAQ:CDXS) shares rose 5.81% to $2.91. The market value of their outstanding shares is at $203.2 million.

    Losers

    • Kiora Pharmaceuticals (NASDAQ:KPRX) stock declined by 10.6% to $0.76 during Thursday's after-market session. The company's market cap stands at $5.8 million.
    • Cingulate (NASDAQ:CING) shares fell 7.74% to $3.1. The market value of their outstanding shares is at $4.4 million.
    • Adagene (NASDAQ:ADAG) shares fell 7.5% to $3.33. The company's market cap stands at $145.9 million.
    • Sharps Technology (NASDAQ:STSS) shares declined by 7.1% to $0.38. The market value of their outstanding shares is at $5.8 million.
    • Alzamend Neuro (NASDAQ:ALZN) shares fell 7.03% to $0.81. The company's market cap stands at $5.3 million.
    • Redhill Biopharma (NASDAQ:RDHL) shares fell 6.48% to $0.56. The market value of their outstanding shares is at $16.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG
    $ALZN
    $BRTX
    $CDXS

    CompanyDatePrice TargetRatingAnalyst
    Adagene Inc.
    $ADAG
    11/24/2025$9.00Buy
    Guggenheim
    Adagene Inc.
    $ADAG
    8/6/2025$7.00Outperform
    Leerink Partners
    Adagene Inc.
    $ADAG
    1/31/2025Overweight → Equal-Weight
    Morgan Stanley
    Cingulate Inc.
    $CING
    1/10/2025$12.00Buy
    ROTH MKM
    Lineage Cell Therapeutics Inc.
    $LCTX
    8/20/2024$4.00Buy
    Craig Hallum
    Codexis Inc.
    $CDXS
    8/19/2024Buy → Hold
    The Benchmark Company
    Codexis Inc.
    $CDXS
    6/3/2024$5.00Buy
    Jefferies
    Codexis Inc.
    $CDXS
    5/30/2024$11.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ADAG
    $ALZN
    $BRTX
    $CDXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Culley Brian M bought $24,375 worth of shares (15,000 units at $1.62), increasing direct ownership by 6% to 255,516 units (SEC Form 4)

    4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

    3/12/26 4:05:10 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ALZN
    $BRTX
    $CDXS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Cingulate Inc.

    DEFA14A - Cingulate Inc. (0001862150) (Filer)

    3/18/26 4:30:04 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Cingulate Inc.

    10-K - Cingulate Inc. (0001862150) (Filer)

    3/18/26 8:13:46 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Cingulate Inc. (0001862150) (Filer)

    3/18/26 8:10:33 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ALZN
    $BRTX
    $CDXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Adagene with a new price target

    Guggenheim initiated coverage of Adagene with a rating of Buy and set a new price target of $9.00

    11/24/25 8:15:55 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Adagene with a new price target

    Leerink Partners initiated coverage of Adagene with a rating of Outperform and set a new price target of $7.00

    8/6/25 7:24:59 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene downgraded by Morgan Stanley

    Morgan Stanley downgraded Adagene from Overweight to Equal-Weight

    1/31/25 8:29:36 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ALZN
    $BRTX
    $CDXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

    New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company's proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 Orthopaedic Research Society Annual Meeting MELVILLE, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that new blinded data on approximately 45 patients from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc dise

    3/19/26 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, "Cingulate delivered on key inflection points throughout 2025 and this continues i

    3/18/26 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

    SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year's AACR Meeting, taking place April 17-22 in San Diego, CA. The following abstracts have been selected for presentation at AACR 2026: Title: Ph1b evaluation of ADG126 (muzastotug, an anti-CTLA-4 masking antibody) pembrolizumab (Pembro) IO doublet in combination with fruquintinib (Fruq) in advanced and metastatic microsatellite stable colorectal cancerSession Title: Phase I Clinical Trials in Pr

    3/17/26 4:35:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ALZN
    $BRTX
    $CDXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Tsimchi Ofer

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/19/26 7:35:14 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Scruggs Rick D

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/18/26 1:16:07 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Reed Kenneth

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/18/26 1:14:09 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ALZN
    $BRTX
    $CDXS
    Leadership Updates

    Live Leadership Updates

    View All

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

    Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (ND

    11/10/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $ADAG
    $ALZN
    $BRTX
    $CDXS
    Financials

    Live finance-specific insights

    View All

    Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

         Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. "Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis

    3/11/26 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Positive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements Successfully Demonstrated the High-Scale Production Potential of Our Proprietary AlloSCOPE™ Manufacturing Platform Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss Initiated Manufacturing Scale Research Project in Type 1 Diabetes Treated First-Ever Chronic SCI Patient in OPC1 DOSED Device Safety Study Current Cash and Equivalents E

    3/5/26 4:01:00 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its fourth quarter and full year 2025 financial and operating results on Thursday, March 5, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the

    2/26/26 8:00:00 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAG
    $ALZN
    $BRTX
    $CDXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.

    SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

    11/21/24 8:05:56 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care